DLD Asset Management LP Acquires New Shares in Eli Lilly and Company $LLY

DLD Asset Management LP bought a new position in shares of Eli Lilly and Company (NYSE:LLY) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,116 shares of the company’s stock, valued at approximately $1,649,000.

Several other large investors have also modified their holdings of LLY. Braun Bostich & Associates Inc. lifted its position in Eli Lilly and Company by 2.5% in the second quarter. Braun Bostich & Associates Inc. now owns 527 shares of the company’s stock valued at $411,000 after buying an additional 13 shares during the last quarter. Rise Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 1.8% in the 2nd quarter. Rise Advisors LLC now owns 732 shares of the company’s stock worth $571,000 after acquiring an additional 13 shares during the last quarter. Occidental Asset Management LLC lifted its holdings in shares of Eli Lilly and Company by 0.7% in the 2nd quarter. Occidental Asset Management LLC now owns 1,966 shares of the company’s stock worth $1,533,000 after acquiring an additional 13 shares during the last quarter. New Insight Wealth Advisors boosted its position in shares of Eli Lilly and Company by 3.4% during the 2nd quarter. New Insight Wealth Advisors now owns 394 shares of the company’s stock worth $307,000 after purchasing an additional 13 shares during the period. Finally, Dash Acquisitions Inc. increased its holdings in Eli Lilly and Company by 2.8% in the 2nd quarter. Dash Acquisitions Inc. now owns 485 shares of the company’s stock valued at $387,000 after purchasing an additional 13 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,105.45 on Thursday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,111.99. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The firm has a market capitalization of $1.05 trillion, a PE ratio of 72.25, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The business’s fifty day moving average price is $876.09 and its 200 day moving average price is $794.85.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same period in the previous year, the business earned $1.18 EPS. Eli Lilly and Company’s revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be paid a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.5%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Wall Street Analysts Forecast Growth

LLY has been the subject of several research analyst reports. Truist Financial raised their price target on Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the stock a “buy” rating in a research report on Wednesday, November 19th. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Daiwa Capital Markets increased their price target on shares of Eli Lilly and Company from $700.00 to $940.00 in a research report on Monday, November 10th. Daiwa America lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. Finally, Leerink Partners raised shares of Eli Lilly and Company from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $886.00 to $1,104.00 in a research note on Monday, November 10th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,047.50.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.